We are live on ! Find out more
BIAFW icon

bioAffinity Technologies
BIAFW

6 hedge funds and large institutions have $137K invested in bioAffinity Technologies in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

4.05% more ownership

Funds ownership: 0%4.05% (+4.1%)

Holders
6
Holders Change
+6
Holders Change %
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$72K +$212K +204,082 New
BFM
2
Boothbay Fund Management
New York
$36K +$13K +12,500 New
CS
3
Clear Street
New York
$9K +$25.9K +25,000 New
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$9K +$27.1K +26,185 New
WAM
5
Warberg Asset Management
Illinois
$7K +$20.1K +19,426 New
UBS Group
6
UBS Group
Switzerland
$4K +$12.1K +11,712 New

BIAFW Hedge Fund Activity: Q3 2022 in Review

6 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2022, worth a combined $137K.

Buyers outnumbered sellers: 6 funds opened new BIAFW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $212K.

  • 6 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $137K of bioAffinity Technologies stock for Q3 2022.
  • 6 funds opened new bioAffinity Technologies positions in Q3 2022 and 0 closed out, a net change of +6 holders.
  • The largest bioAffinity Technologies buyer in Q3 2022 was Armistice Capital, an estimated $212K added.

Based on aggregated 13F filings for Q3 2022.